A Study of Pegylated Liposomal Doxorubicin and Cyclophosphamide in Her2-negative Stage I and II Breast Cancer Patients

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2010
Primary objective: * To evaluate the disease-free survival (DFS) in the two randomized arms after therapy with LC vs. EC in chemo-naive Her2-patients with stage I or II breast cancer Secondary objectives: * To assess the overall survival (OS) * To establish the safety profile by assessing the toxicities and tolerability * To assess the quality of life (QoL) * To evaluate survival correlation with biomarkers expression.
Epistemonikos ID: 2de47cf9af5271cdaf6b53d5933aca3cfd6fd1a4
First added on: May 05, 2024